Toronto Dominion Bank Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Toronto Dominion Bank boosted its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 22.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 5,546 shares of the biotechnology company’s stock after purchasing an additional 1,021 shares during the quarter. Toronto Dominion Bank’s holdings in United Therapeutics were worth $1,987,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. LSV Asset Management grew its holdings in shares of United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares during the last quarter. World Investment Advisors LLC bought a new position in United Therapeutics in the 3rd quarter valued at approximately $139,206,000. FMR LLC boosted its stake in United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after purchasing an additional 314,004 shares during the last quarter. Assetmark Inc. increased its holdings in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares in the last quarter. Finally, Pacer Advisors Inc. raised its stake in shares of United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after purchasing an additional 92,240 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on UTHR shares. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $361.81 on Monday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The business has a fifty day moving average price of $369.94 and a 200-day moving average price of $342.71. The firm has a market capitalization of $16.15 billion, a price-to-earnings ratio of 15.89, a price-to-earnings-growth ratio of 1.05 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter last year, the company earned $5.38 earnings per share. On average, equities research analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Judy D. Olian sold 1,750 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the sale, the director now owns 5,655 shares in the company, valued at approximately $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the sale, the executive vice president now directly owns 36,710 shares in the company, valued at $13,743,122.70. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 119,340 shares of company stock worth $44,765,530. Company insiders own 11.90% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.